Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
7,998
Period ended Dec 31, 2025
Change on a year earlier
+17.5%
6,805 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7,998 | +17.5% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 6,805 | +18.1% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 5,761 | +21.1% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 4,756 | +9.9% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 4,328 | +32.5% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 3,267 | +29.4% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 2,524 | +30.6% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 1,933 | +36.7% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 1,414 | +23.8% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 1,142 | +2.2% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 1,117 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up diabetes care division (freestyle libre cgm & blood glucose monitoring) — worldwide revenue ($m)
- Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Organic / Comparable Sales Growth (%)16.3% · FY2025
- Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Reported Sales Growth (%)17.5% · FY2025
- Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Foreign Exchange Impact on Sales Growth (%)1.2% · FY2025
- Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — U.S. Revenue ($M)3,181 · FY2025
- Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — International Revenue ($M)4,817 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Diabetes Care Division (FreeStyle Libre CGM & Blood Glucose Monitoring) — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-dc-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.